Dr. Elham S. Ghorbani, MD
General Practice (General Practice Physician)
At a glance
- In the NPI registry since
- 2022
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2022Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
General Practice Physician primary
PR license 22625
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $246 in total to this clinician.
| Novo Nordisk Inc | $125 |
|---|---|
| Madrigal Pharmaceuticals | $121 |
| Food and Beverage | $246 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 4 companies. The companies reported $612,196 in research payments for these studies, mostly to the institutions running them.
- A master protocol to investigate the efficacy and safety of orforglipron tablet once daily compared with placebo in participants with obesity or overweight with and without type 2 diabetes: J2A-mc-GZP1, J2A-mc-GZP2
Eli Lilly Export S.a. Puerto Rico Branch - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OA…
Amgen Inc. - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OAS…
Amgen Inc. - A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396574 - A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company · Completed · NCT05971940 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
AbbVie Inc. · Enrolling by invitation · NCT05127954 - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. - A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396236 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.